CDK7 and ovarian cancer: SY-5609 is another selective CDK7 inhibitor and preclinical testing has demonstrated that SY-5609 and Fulvestrant together exhibit strong anti-cancer action against ER+ breast cancer, TNBC, and ovarian cancer (Diab et al., 2020[30]; Kovalová et al., 2023[62]).